Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Burchardt, Norah Ana [VerfasserIn]   i
 Shafrir, Amy L. [VerfasserIn]   i
 Kaaks, Rudolf [VerfasserIn]   i
 Tworoger, Shelley S. [VerfasserIn]   i
 Turzanski Fortner, Renée [VerfasserIn]   i
Titel:Oral contraceptive use by formulation and endometrial cancer risk among women born in 1947-1964
Titelzusatz:the Nurses’ Health Study II, a prospective cohort study
Verf.angabe:Norah A. Burchardt, Amy L. Shafrir, Rudolf Kaaks, Shelley S. Tworoger, Renée T. Fortner
Jahr:2021
Umfang:13 S.
Fussnoten:Published online: 17 December 2020 ; Gesehen am 15.01.2024
Titel Quelle:Enthalten in: European journal of epidemiology
Ort Quelle:[Cham] : Springer Nature Switzerland AG, 1985
Jahr Quelle:2021
Band/Heft Quelle:36(2021), 8, Seite 827-839
ISSN Quelle:1573-7284
Abstract:Oral contraceptives (OCs) have been associated with long-term lower endometrial cancer risk; relatively little is known about associations with more recent OC formulations and associations with longer-term risk. A total of 107,069 women from the Nurses’ Health Study II recalled OC use from age 13 to baseline (1989); biennial questionnaires updated data on OC use until 2009. OCs were classified by estrogen and progestin type, dose, and potency based on reported brand. 864 incident endometrial cancer cases were identified through 2017. Multivariable Cox proportional hazards models estimated hazard ratios (HR) and 95% confidence intervals [95% CI] for the association of OC use with endometrial cancer risk. OC use was associated with lower endometrial cancer risk (ever use, HR 0.77 [95% CI 0.65-0.91]; >10 years of use, 0.43 [0.32-0.58] vs. never OC use). Inverse associations for duration were evident regardless of time since last use. Longer durations (> 5 years) of ethinyl estradiol (0.52 [0.41-0.67]) and second-generation progestins (0.43 [0.30-0.61]), both versus never use, were more strongly associated with lower risk than mestranol (0.66 [0.50-0.88], p-het = 0.01) and first-generation progestins (0.62 [0.49-0.78], p-het = 0.03). Inverse associations were generally observed for cross-classified cumulative average estrogen and progestin dose and potency (< vs. ≥ median; ever use vs. never OC use), with the exception of high estrogen and low progestin dose. OCs were associated with lower endometrial cancer risk, independent of time since last use. Use of ethinyl estradiol and second-generation progestins were more strongly inversely associated with risk compared with older formulations.
DOI:doi:10.1007/s10654-020-00705-5
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

kostenfrei: Volltext: https://doi.org/10.1007/s10654-020-00705-5
 kostenfrei: Volltext: https://link.springer.com/article/10.1007/s10654-020-00705-5
 DOI: https://doi.org/10.1007/s10654-020-00705-5
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Endometrial cancer
 Hormonal contraceptives
 Oral contraceptives
K10plus-PPN:1878111442
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69161248   QR-Code
zum Seitenanfang